Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Jul
18
Today In Oncology
COVID-19 Boosters Offer Protection for Patients With Cancer
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
Classifying Pancreatic Cysts Using AI Models
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo